On April 1, 2024, TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company, announced the execution of a non-binding letter of intent (LOI) with an unnamed cell therapy company for the potential acquisition of several assets. These assets include a Solid Tumor tool kit, a NK Cell Manufacturing tool kit, and two CAR-NK programs. The terms of the acquisition involve a combination of cash, equity at closing, and milestone payments based on clinical achievements. The LOI indicates mutual interest and the final terms are subject to due diligence, definitive agreements, and various contingencies such as securing adequate financing and receiving necessary approvals. The completion of the transaction is uncertain, and there is no guarantee that it will proceed as contemplated...Show More

On April 1, 2024, TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company, announced the execution of a non-binding letter of intent (LOI) with an unnamed cell therapy company for the potential acquisition of several assets. These assets include a Solid Tumor tool kit, a NK Cell Manufacturing tool kit, and two CAR-NK programs. The terms of the acquisition involve a combination of cash, equity at closing, and milestone payments based on clinical achievements. The LOI indicates mutual interest and the final terms are subject to due diligence, definitive agreements, and various contingencies such as securing adequate financing and receiving necessary approvals. The completion of the transaction is uncertain, and there is no guarantee that it will proceed as contemplated or at all. The acquisition is part of TC BioPharm's M&A strategy to expand its therapeutic platform, leveraging NK cells for treating solid tumors and other indications. The company sees potential synergies with its existing TCB-008 therapy and aims to enhance its position in cell therapy. The announcement was made in a press release dated April 4, 2024, and is accompanied by forward-looking statements regarding the company's intentions and the potential impact of the acquisition.